KERYX BIOPHARMACEUTICALS INC (KERX) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 549 transactions totaling $39.8M, demonstrating a bearish sentiment with -$37.6M in net insider flow. The most recent transaction on Dec 12, 2018 involved a transaction of 65,374,013 shares valued at $0.
No significant insider buying has been recorded for KERX in the recent period.
No significant insider selling has been recorded for KERX in the recent period.
Based on recent SEC filings, insider sentiment for KERX is bearish with an Insider Alignment Score of 3/100 and a net flow of -$37.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at KERYX BIOPHARMACEUTICALS INC (KERX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading KERX stock, having executed 549 transactions in the past 90 days. The most active insider is Group Llc/ma Baupost (Executive), who has made 3 transactions totaling $164.7M.
Get notified when executives and directors at KERX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 12, 2018 | Llc/ma Baupost Group | Executive | Disposition | 65,374,013 | $N/A | $0 | |
| Dec 12, 2018 | A. Carberry Christine | Executive | Disposition | 100,646 | $N/A | $0 | |
| Dec 12, 2018 | J. Cameron Kevin | Executive | Disposition | 186,666 | $N/A | $0 | |
| Dec 12, 2018 | F. Neylan John | Executive | Disposition | 148,279 | $N/A | $0 | |
| Dec 12, 2018 | C. Gilman Steven | Executive | Disposition | 27,333 | $N/A | $0 | |
| Dec 12, 2018 | Thomas Heffernan Michael | Executive | Disposition | 20,000 | $N/A | $0 | |
| Dec 12, 2018 | Paul Regan Daniel | Executive | Disposition | 60,000 | $N/A | $0 | |
| Dec 12, 2018 | Pope Morrison Jodie | Executive | Disposition | 120,000 | $N/A | $0 | |
| Dec 12, 2018 | A. Holmes Scott | Executive | Disposition | 162,956 | $N/A | $0 | |
| Dec 12, 2018 | J. Enyedy Mark | Executive | Disposition | 10,000 | $N/A | $0 | |
| Dec 12, 2018 | W. Rogers Michael | Executive | Disposition | 30,000 | $N/A | $0 | |
| Dec 11, 2018 | Llc/ma Baupost Group | Executive | Award | 4,000,000 | $N/A | $0 | |
| Dec 11, 2018 | Llc/ma Baupost Group | Executive | Award | 35,582,335 | $4.63 | $164.7M | Large |
| Dec 11, 2018 | A. Carberry Christine | Executive | Sale | 10,469 | $3.22 | $33.7K | |
| Nov 15, 2018 | A. Holmes Scott | Executive | Sale | 1,155 | $2.77 | $3.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 100 | $164.8M | 79.3% |
Sale(S) | 357 | $38.7M | 18.6% |
Exercise(M) | 29 | $2.3M | 1.1% |
Purchase(P) | 39 | $1.1M | 0.5% |
Payment(F) | 4 | $585.4K | 0.3% |
Gift(G) | 8 | $390.6K | 0.2% |
Disposition(D) | 11 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at KERYX BIOPHARMACEUTICALS INC has increased, with 29 insiders executing 549 transactions across all time. Total sales of $38.7M significantly outpace purchases of $1.1M, resulting in a net outflow of $37.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.